DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Jones RH, Carucci M, Casbard AC. et al.
Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.
J Clin Oncol 2019;
37: Abstr. 1005
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.